Thursday, July 27, 2006

Intevac, Illumina, Hansen Natural Corporation and Celgene Corporation

Zacks.com Announces That Jim Collins Highlights the Following Stocks: Intevac, Illumina, Hansen Natural Corporation and Celgene Corporation


Jim Collins, editor of the OTC Insight newsletter, believes that fundamentals suggest stocks will eventually come back strong. Read about Intevac (Nasdaq:IVAC), Illumina (Nasdaq:ILMN), Hansen Natural Corporation (Nasdaq:HANS) and Celgene Corporation (Nasdaq:CELG). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84.


Highlights from the July 17 Featured Expert column by Jim Collins include:

A Sampling of Company News...

Intevac (Nasdaq:IVAC) shares are higher after the company said last Tuesday full-year sales would top previous projections. Earlier, the company announced it received orders from multiple customers for a total of eleven 200 Lean magnetic disk sputtering systems. Intevac said that with these orders they have booked enough systems to not only exceed the high end of their previous revenue guidance for 2006, but also provide an excellent start for 2007.

Illumina (Nasdaq:ILMN) has signed a genotyping services agreement with Johnson & Johnson Pharmaceutical Research & Development. Under the terms of the agreement, Illumina will develop custom SNP (single nucleotide polymorphism) content for a multi-sample Sentrix BeadChip. The BeadChip platform enables analysis of 12 samples and up to 60,000 SNPs per sample on a single BeadChip.

Stock Picks include...

Hansen Natural Corporation (Nasdaq:HANS) is a holding company and carries on no operating business except through its direct wholly-owned subsidiaries, Hansen Beverage Company and Hard e Beverage Company. Hansen is engaged in the business of marketing, selling and distributing so-called alternative beverage category, such as natural sodas, fruit juices, juice cocktails.

Celgene Corporation (Nasdaq:CELG) is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Read Jim Collins' outlook regarding the stock market's come back and receive more company news as well as stock picks by clicking: http://at.zacks.com/?id=85.

About Zacks Featured Experts

Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Each issue highlights several Featured Experts in this free e-mail newsletter. Register for a free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=87.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home